Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Recursion Pharmaceuticals, Inc. - Class A Common Stock
(NQ:
RXRX
)
3.200
+0.040 (+1.27%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 11, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
23
24
Next >
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
April 16, 2024
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
↗
April 15, 2024
With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks.
Via
InvestorPlace
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for April 2024
↗
April 15, 2024
Through opportunity for growth and strong financial performance, these three Cathie Wood stocks could provide generous returns.
Via
InvestorPlace
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
↗
April 15, 2024
The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases.
Via
Talk Markets
Topics
Artificial Intelligence
Analyst Scoreboard: 5 Ratings For Recursion Pharmaceuticals
↗
April 09, 2024
Via
Benzinga
Forecasting The Future: 4 Analyst Projections For Recursion Pharmaceuticals
↗
March 04, 2024
Via
Benzinga
Cathie Wood's Ark Invest Sells $20M+ Coinbase Shares As Bitcoin Trades Over $70K, Buys Palantir, Sells Nvidia Stock
↗
April 11, 2024
On Thursday, Cathie Wood’s Ark Invest made significant trades involving Coinbase Global, Inc. (NASDAQ:COIN), Palantir Technologies Inc. (NYSE:PLTR), and Nvidia Corp.
Via
Benzinga
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.
↗
April 10, 2024
Recursion is playing the long game with its AI-focused approach to drug discovery and development.
Via
The Motley Fool
The AI Advantage: 2 Healthcare Stocks at the Forefront of Innovation
↗
April 08, 2024
They might not be profitable yet, but they're swinging for the fences.
Via
The Motley Fool
Topics
Artificial Intelligence
AI Surge Ending: Only One Category Was Up This Week
↗
April 06, 2024
Six of the 7 categories we cover dropped this week, compared with 3 in March. The data clearly indicates that the surge in this sector is stalling or perhaps is even over.
Via
Talk Markets
Topics
Artificial Intelligence
Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy?
↗
April 04, 2024
This stock's upside is huge, but so is its downside.
Via
The Motley Fool
Topics
Artificial Intelligence
Recursion to Participate in Upcoming Investor Conference
April 02, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
AI Sector Stalling: Only 4 Of 7 Categories Went Up In March
↗
March 31, 2024
No AI category went down in February, but 3 did in March - confirming my comment last week that
Via
Talk Markets
Topics
Artificial Intelligence
Cathie Wood's Ark Invest Continues To Double Down On Moderna, Sells Nvidia Shares
↗
March 26, 2024
Via
Benzinga
Recursion Publishes Annual Environmental, Social and Governance Report
March 26, 2024
Provides progress updates in support of long-term commitments focused on reducing greenhouse gas emissions, improving workforce diversity and accelerating community impact.
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Nvidia's AI Revolution Is Transforming Healthcare with Johnson & Johnson and GE Healthcare Partnerships
↗
March 25, 2024
Nvidia announces partnerships with J&J and GE Healthcare to integrate generative AI into surgery and medical imaging at GTC AI conference. Analysts see potential for revenue growth outside tech sector....
Via
Benzinga
Topics
Artificial Intelligence
New COVID-Like Outbreak 'Matter Of When, Not If,' WHO Director Warns As Scientists Race To Prepare Using Artificial Intelligence
↗
March 18, 2024
Via
Benzinga
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
March 13, 2024
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24...
Via
Benzinga
Nvidia's Secret Weapon Is Not Just Chips But Investing $1.5B In AI's Rising Stars: Report Unveils CEO Jensen Huang's 10-Year Vision
↗
March 11, 2024
Additionally, the investments help Nvidia "build out the future ecosystem of businesses that depend on its technology" even as rivals are trying to break into the chipmaker's dominance.
Via
Benzinga
Topics
Artificial Intelligence
Recursion Announces Plans to Open New Office in London
March 11, 2024
Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the...
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst
↗
March 07, 2024
The company just made a provocative move in one of its collaborations.
Via
The Motley Fool
The Top 7 Small-Cap Stocks to Buy in March 2024
↗
March 04, 2024
These top small-cap stocks to buy are set for a strong 2024 as reduced inflation increases their growth prospects.
Via
InvestorPlace
Topics
Economy
The Top 3 Healthcare Stocks to Buy on Weakness in 2024
↗
March 04, 2024
Many healthcare stocks have extremely bright outlooks and very low valuations. Here are three top healthcare stocks to buy.
Via
InvestorPlace
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
↗
March 04, 2024
Grand View Research says the global
Via
Talk Markets
Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
March 01, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?
↗
March 01, 2024
On the leading edge of rare disease treatment and therapy is where you will find these Cathie Wood biotech stocks.
Via
InvestorPlace
Recursion to Participate in Upcoming Investor Conferences
March 01, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Why Recursion Pharmaceuticals Stock Dived by Nearly 17% Today
↗
February 28, 2024
The company had attracted much interest due to its heavy use of artificial intelligence, but its latest fundamentals disappointed many.
Via
The Motley Fool
Topics
Artificial Intelligence
Why Beyond Meat Shares Are Trading Higher By Around 56%; Here Are 20 Stocks Moving Premarket
↗
February 28, 2024
Shares of Beyond Meat, Inc. (NASDAQ: BYND) rose sharply in today’s pre-market trading as the company reported stronger-than-expected sales for its fourth quarter.
Via
Benzinga
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
February 28, 2024
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.
Via
Benzinga
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
23
24
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.